World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
52897
World Ranking
8432
National Ranking
4359

Kathy S. Albain publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kathy S. Albain sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 403 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kathy S. Albain D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kathy S. Albain sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kathy S. Albain is affiliated with Loyola University Chicago in the United States. Their research focuses primarily on fields within medicine, specifically oncology and cancer research. Subfields of particular interest include pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, as well as genetics.

Their scholarly work spans several critical topics related to cancer and breast cancer treatment, including:

  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Immunotherapy and Biomarkers

Kathy S. Albain has published extensively in several journals with high output particularly in:

  • Cancer Research
  • Journal of Clinical Oncology
  • UNC Libraries
  • JAMA Oncology
  • npj Breast Cancer

Notable recent papers include:

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer, 2020, JAMA Oncology
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial, 2021, Cancer Cell
  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer, 2020, JAMA Oncology
  • Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival, 2020, JNCI Journal of the National Cancer Institute

The research collaborations of Kathy S. Albain include frequent co-authorship with several scholars such as:

  • Lajos Pusztai
  • Hope S. Rugo
  • Claudine Isaacs
  • Rita Nanda
  • Laura J. Esserman

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

    Laura F. Hutchins;Joseph M. Unger;John J. Crowley;Charles A. Coltman

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

    Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

    Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow

  • Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

    Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice

  • Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

    Kathy S. Albain;John J. Crowley;Michael LeBlanc;Robert B. Livingston

  • Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.

    M M Le Beau;K S Albain;R A Larson;J W Vardiman

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study

    Antoinette J. Wozniak;John J. Crowley;Stanley P. Balcerzak;Geoffrey R. Weiss

  • Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

    Karen Kelly;Kari Chansky;Laurie E. Gaspar;Kathy S. Albain

  • The Global Breast Cancer Burden: Variations in Epidemiology and Survival

    Gabriel N. Hortobagyi;Jaime de la Garza Salazar;Kathleen Pritchard;Dino Amadori

  • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

    Halle C F Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle

  • Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

    Nicholas Robert;Brian Leyland-Jones;Lina Asmar;Robert Belt

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

    Rita Nanda;Minetta C Liu;Christina Yau;Rebecca Shatsky

  • Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Hope S. Rugo;Olufunmilayo I. Olopade;Angela DeMichele;Christina Yau

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
Claudine Isaacs
Claudine Isaacs Georgetown University
David R. Gandara
David R. Gandara University of California, Davis
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
William E. Barlow
William E. Barlow Fred Hutchinson Cancer Research Center
Robert B. Livingston
Robert B. Livingston University of Arizona
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Dawn L. Hershman
Dawn L. Hershman Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

There are numerous online degrees in healthcare that can complement or provide alternative pathways to traditional medical studies in the USA. For those aiming for healthcare leadership roles rather than becoming a physician, online mha programs cahme accredited offer flexible, respected routes into hospital administration and health services management.

Registered nurses looking to advance their education might consider rn to bsn programs without clinicals. These programs are ideal for working nurses seeking career growth without the need for additional clinical hours, making them both efficient and accessible.

For nurses aspiring to reach the highest level of practice, options like the fastest dnp program can dramatically shorten the time required for a Doctor of Nursing Practice degree. Some may also prefer dnp programs without dissertation which eliminate the need for lengthy research projects, allowing students to focus on clinical leadership and patient care.

Exploring these alternative online healthcare degrees opens doors to a diverse range of career opportunities within the medical field, providing flexibility and targeted professional growth for both aspiring and current healthcare professionals.

Best Scientists Citing Kathy S. Albain

Trending Scientists

Recently Published Articles